A Phase 2 interventional study of Entecavir and Lamivudine in Hepatitis B Virus and HBV, sponsored by Bristol-Myers Squibb. Completed. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-08-23.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies testing entecavir in Hepatitis B — 6 open to participants now, 9 under way, none of them phase 3. entecavir · Hepatitis B.
Among the 37 studies testing entecavir in Hepatitis B, this one has the largest enrollment of the 36 interventional ones that give a count, is the only one that started in 2001, is one of 5 in phase 2, and was the 13th registered.
1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.
Browse Hepatitis B studies →6 of the 37 studies testing entecavir in Hepatitis B are open now, in 4 countries. Recruiting first, the newest first:
Bangladesh Medical University · Sites in Bangladesh
Ages 18+ · Men only
University Health Network, Toronto · Sites in Canada
Ages 18+
Ascentage Pharma Group Inc. · Sites in China
Ages 18+
Taichung Veterans General Hospital · Sites in Taiwan
Ages 20+
Qing-Lei Zeng
Ages 3–6
By country, each count listing its studies:
entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 6 · Phase 4 20
First in 2001; this study’s year is marked. 1 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,053 is above the median of 145 across 756 interventional studies indexed under Hepatitis B.
Median enrollment 106 across the 36 interventional studies. Of the 17 that completed or were terminated, 6 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 37 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
12 studies in Hepatitis B by Bristol-Myers Squibb: none open now, none under way, none of them phase 3. Of 11 finished, 5 (45%) have results posted.
Among the 12 studies in Hepatitis B by Bristol-Myers Squibb, this one is the only one that started in 2001, is one of 2 in phase 2, and was the 8th registered.
Bristol-Myers Squibb’s Hepatitis B studies by the year they started, since 2001.
3 of the studies testing entecavir in Hepatitis B that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05453435Sun Yat-sen UniversityEntecavir Prophylaxis for Hepatitis B Reactivation for CD20 Positive B-cell Lymphoma Patients With Resolved Hepatitis B (Negative Hepatitis B Surface Antigen, Positive Hepatitis B Core Antibody) | 2026-12 |
| NCT07816094Bangladesh Medical UniversityComparison of Viral Suppression With 0.5 mg and 1.0 mg Daily Doses of Entecavir in Decompensated HBV Cirrhosis of Liver | 2027-01-19 |
| NCT07189377University Health Network, TorontoCombined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 37 studies testing entecavir in Hepatitis B, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 12 in Hepatitis B:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide entecavir to participants who have completed another entecavir trial without achieving virologic response or who relapsed during postdosing follow-up.
Key inclusion criteria:
Participants who were, based on their response to entecavir:
Complete responders who during postdosing follow-up
Demonstrated intolerance to adefovir
Key exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Entecavir · Drug: Lamivudine
Tablets, Oral, 1.0 mg, once daily
Also known as: Baraclude
Oral, 100 mg, daily
Overall Study: Number of Participants With Death As Outcome, Any Adverse Event (AE), Grade 3-4 AEs, Serious Adverse Events (SAEs), and Discontinuations Due to AEs
An AE is a new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not be causally related to treatment. An SAE is an unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling. ALT=alanine transaminase; ULN=upper limit of normal.
Time frame: Continuously from Day 1 through Week 240
Overall Study: Number of Participants With Normal Hematology Values at Baseline and Abnormalities in Hematology Laboratory Test Results Through Week 240
Hemoglobin (g/dL): Grade (Gr) 1=9.5-11.0; Gr 2=8.0-\<9.5; Gr 3=6.5-\<8.0; Gr 4=\<6.5 White blood cells (cells/mm\^3): Gr 1=2,500-\<4,000; Gr 2=1,000-\<2,500; Gr 3=800-\<1,000; Gr 4=\<800. Neutrophils (cells/mm\^3): Gr 1=1000-\<1500; Gr 2=750-\<1000; Gr 3=500-\<750; Gr 4=\<500. Platelets (cells/mm\^3): Gr 1=75,000-99,000; Gr 2=50,000-\<75,000; Gr 3=20,000-\<50,000; Gr 4=\<20,000. Prothrombin time (seconds): Gr 1=1.01-\<1.26\*ULN; Gr 2=1.26-\<1.51 \*ULN; Gr 3=1.51-3\*ULN; Gr 4=\>3\*ULN. INR: Gr 1=1.24-1.5; Gr 2=1.5-2; Gr 3=2-3; Gr 4=\>3. INR=international normalized ratio; ULN=upper limit of normal. .
Time frame: Day 1 of treatment through Week 240
Overall Study: Number of Participants With Normal Pancreatic Enzyme and Renal Function Values at Baseline and Abnormalities in Pancreatic Enzyme and Renal Function Laboratory Test Results at End of Dosing
Amylase: Grade 1=1.10-\<1.40\*ULN; Grade 2=1.40-\< 2.10\*ULN; Grade 3=2.10-5.00\*ULN; Grade 4=\>5.00\*ULN. Lipase: Grade 1.1-\<1.4\*ULN; Grade 2=1.4-\<2.1\*ULN; Grade 3=2.1-5.0\*ULN; Grade 4=\>5.0\*ULN. Creatinine: Grade 1=1.10-\< 1.60\*ULN; Grade 2=1.60-\<3.10\*ULN; Grade 3=3.10-6.00\*ULN; Grade 4=\>6.00\*ULN. Blood urea nitrogen (BUN): Grade 1=1.25-\<2.60\*ULN; Grade 2=2.60-\<5.10\*ULN; Grade 3=5.10-10\*ULN; Grade 4=\>10\*ULN. ULN=upper limit of normal.
Time frame: Day 1 of treatment through Week 240
Overall Study: Number of Participants With Normal Electrolyte and Fasting Glucose Values at Baseline and Abnormalities in Electrolyte and Fasting Glucose Laboratory Test Results at End of Dosing
Hypochloremia: Grade (Gr) 1=90-93; Gr 2=85-\<90; Gr 3=80-\<85; Gr 4=40-\<80. Hyperchloremia: Gr 1=113-\<117; Gr 2=117-\<121; Gr 3=121-125; Gr 4\>125. Hypocarbia: Gr 1=19-21; Gr 2=15-\<19; Gr 3=41-45; Gr 4=\>45. Hypercarbia: Gr 1=31-36; Gr 2=37-40; Gr 3=41-45; Gr 4=\>45. Hyponatremia: Gr 1=130-132; Gr 2=123-\<130; Gr 3=116-\<123; Gr 4\<116. Hypernatremia: Gr 1=148-\<151; Gr 2=151-\<158; Gr 3=158-165; Gr 4=\>165. Hypokalemia: Gr 1=3-3.4; Gr 2=2.5-\<3; Gr 3=2-\<2.5; Gr 4=\<2. Hyperkalemia: Gr 1=5.6-\<6.1; G2=6.1-\<6.6; Gr 3=6.6-7; Gr 4=\>7. Hypoglycemia: Gr 1=55-64; Gr 2=40-\<55; Gr 3=30-\< 40; G4=-\<30. Hyperglycemia: Gr 1=116-\<161; Gr 2=161-\<251; Gr 3=251-500; Gr 4\>500.
Time frame: Day 1 of treatment through Week 240
Week 144: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling. AST=aspartate aminotransferase; ULN=upper limit of normal.
Time frame: Continuously from Day 1 through Week 144
Week 192: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. CTC Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling. ALT=alanine aminotransferase; ULN=upper limit of normal.
Time frame: Continuously from Day 1 through Week 192
Off-treatment Follow-up: Percentage of Participants With Sustained Hepatitis B Virus (HBV) DNA <10,000 Copies by Polymerase Chain Reaction (PCR) Assay (Amendment 11 Cohort)
The Amendment 11 Cohort consisted of participants who were hepatitis B e antigen (HBeAg) negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA \<300 copies/mL by PCR assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0\*ULN at the end of study drug dosing.ALT=alanine aminotransferase; ULN=upper limit of normal.
Time frame: End of dosing to Week 48 off-treatment follow-up
Overall Study: Percentage of Participants With Sustained HBV DNA Level <300 Copies/mL by PCR Assay
Time frame: Study entry to Week 192
Overall Study: Percentage of Participants With Sustained HBV DNA <10^4 Copies/mL by PCR Assay
Time frame: Study entry to Week 192
Overall Study: Percentage of Participants by HBV DNA Category by PCR Assay
Observed values.
Time frame: Baseline to Week 192
Overall Study: Mean HBV DNA Level by PCR Assay
Time frame: Study entry to Week 216
Overall Study: Percentage of Participants Who Achieved a Loss of Hepatitis B e Antigen (HBeAg)
Observed values.
Time frame: Study entry to Week 216
Overall Study: Percentage of Participants With HBeAg Seroconversion
Observed values. Seroconversion=negative HBeAg with detectable anti-HBe antibody.
Time frame: Study entry to Week 216
Overall Study: Mean Alanine Transaminase (ALT) Levels
Observed values.
Time frame: Study entry to Week 216
Overall Study: Percentage of Participants Who Achieved ALT Normalization
ULN=upper limit of normal. ALT normalization=ALT levels ≤1.0\*ULN.
Time frame: Study entry to Week 216
Week 192: Percentage of Participants With Histologic Improvement (Efficacy Evaluable Cohort)
The Knodell Histologic Activity Index scores stage of necrosis and grade of inflammation in liver biopsies. Components are necrosis near the portal vein, intralobular degeneration and focal necrosis, portal inflammation, and fibrosis. The 4 components are scored from 1 to 4 and 1 to 10 (necrosis near the portal vein) and combined for a total score, with 22 being the highest possible score. Higher the score for each component=greater liver damage. Histologic improvement=a ≥2-point reduction in total Knodell score and no worsening in fibrosis. Cohort participants had to have adequate baseline and long-term biopsy samples and baseline Knodell necroinflammatory scores ≥2.
Time frame: Baseline to Week 192
Week 192: Percentage of Participants With Improvement in Fibrosis (Efficacy Evaluable Cohort)
The Ishak Modification for Hepatic Activity Index (HAI) scores necroinflammatory activity in chronic hepatitis. 0=no fibrosis, 1=fibrosis expansion of some portal areas, 2=fibrosis expansion of most portal areas, 3=fibrosis expansion of most portal areas with occasional bridging, 4=fibrosis expansion of portal areas with marked bridging, 5=incomplete cirrhosis, 6=probable or definite cirrhosis. Higher score=more severe necrosis. Improvement in fibrosis=≥1-point reduction in HAI score. Cohort participants had to have adequate baseline and long-term biopsy samples and baseline Knodell scores ≥2.
Time frame: Baseline to Week 192
Overall Study: Percentage of Participants With a Confirmed ≥1 log10 Increase From Nadir in HBV DNA by PCR Assay
Time frame: Baseline to Week 144
Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAG, Seroconversion, and ALT ≤1.0*Upper Limit of Normal (ULN) (Entecavir Continuous Treatment Cohort)
The Entecavir Continuous Treatment Cohort consisted of participants from study AI463-022 (NCT00035633) who were nucleoside-naive HBeAg-positive and enrolled in the current study with ≤35 days off treatment between the last dose in AI463-022 and the first dose in the current. This cohort is considered to be on continuous entecavir treatment and permitted assessment of continuous administration of entecavir in AI463-022 and the current study.
Time frame: Baseline to Weeks 48, 96, 144, 192, and 240
Percentage of Participants Who Achieved HBV DNA <300 and <10^4 Copies/mL by PCR Assay and ALT ≤1.0*Upper Limit of Normal (ULN) (Entecavir Retreatment Cohort)
The Entecavir Retreatment Cohort consisted of participants who were nucleoside-naive, HBeAg-negative and enrolled from BMS study AI463-027 with \>60 days off treatment between the last dose in AI463-027 and the first dose in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as retreatment in the current study.
Time frame: Baseline to Weeks 48, 96, and 144
Week 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAg, HBeAg Seroconversion, and ALT ≤1.0*ULN (Lamivudine Continuous Switch Cohort)
The Lamivudine Continuous Switch Cohort consisted of participants who were nucleoside-naive, HBeAg-positive and received lamivudine in BMS study AI463-022 (NCT00035633) and enrolled in the current study with ≤35 days off treatment between end of dosing in AI463-022 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
Time frame: Baseline to Week 96
Week 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Continuous Switch Cohort)
The Lamivudine Continuous Switch Cohort consisted of participants who were nucleoside-naive, HBeAg-positive and received lamivudine in BMS study AI463-022 (NCT00035633) and enrolled in the current study with ≤35 days off treatment between end of dosing in AI463-022 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
Time frame: Baseline to Week 144
Week 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Retreatment Switch Cohort)
The Lamivudine Retreatment Switch Cohort consisted of participants who were nucleoside-naive HBeAg negative and enrolled from BMS study AI463-027 (NCT00035789) with \>60 days between end of dosing in AI463-027 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
Time frame: Baseline to Week 96
Week 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Retreatment Switch Cohort)
The Lamivudine Retreatment Switch Cohort consisted of participants who were nucleoside-naive HBeAg negative and enrolled from BMS study AI463-027 (NCT00035789) with \>60 days between end of dosing in AI463-027 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
Time frame: Baseline to Week 144
Off-treatment Follow-up: Percentage of Participants With Sustained HBV DNA <1,000, <300, and <10,000 Copies/mL by PCR Assay and With ALT ≤1*ULN (Amendment 11 Cohort)
The Amendment 11 Cohort consisted of participants who were HBeAg negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA \<300 copies/mL by PCR Assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0\*ULN at the end of study drug dosing. ULN=upper limit of normal.
Time frame: End of dosing to Weeks 48 and 96 off-treatment follow-up
Off-treatment Follow-up: Mean Change in HBV DNA (Amendment 11 Cohort)
The Amendment 11 Cohort consisted of participants who were HBeAg negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA \<300 copies/mL by PCR assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0\*ULN at the end of study drug dosing.
Time frame: End of dosing to Weeks 48 and 96 off-treatment follow-up
| Milestone | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Started | 1051 |
| Completed | 634 |
| Not completed | 417 |
| Withdrew: Continuing treatment | 29 |
| Withdrew: Minimal virologic response | 95 |
| Withdrew: Not identified | 55 |
| Withdrew: Withdrawal by subject | 104 |
| Withdrew: Progression of chronic hepatitis b | 22 |
| Withdrew: Death | 22 |
| Withdrew: Adverse event | 17 |
| Withdrew: Lost to follow-up | 17 |
| Withdrew: Abnormal laboratory test result | 14 |
| Withdrew: Need for drug prohibited by protocol | 14 |
| Withdrew: Pregnancy | 7 |
| Withdrew: No longer met inclusion criteria | 1 |
| Withdrew: Participant noncompliance | 20 |
| Percentage of participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| At study entry (n=1051) | 17 |
| Week 48 (n=905) | 63 |
| Week 96 (n=691) | 67 |
| Week 144 (n=597) | 73 |
| Week 192 (n=485) | 78 |
| Percentage of participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| At study entry (n=1051) | 28 |
| Week 48 (n=905) | 76 |
| Week 96 (n=691) | 77 |
| Week 144 (n=597) | 81 |
| Week 192 (n=485) | 85 |
Observed values.
| Percentage of participants | Entecavir, 1.0 mg, With or Without Lamivudine |
|---|---|
| Baseline: <300 copies/mL (n=1051) | 17 ± 4 |
| Baseline: 300 - <1.0E3 copies/mL (n=1051) | 4 ± 8 |
| Baseline: 1.0E3 - <1.0E4 copies/mL (n=1051) | 8 ± 13 |
| Baseline: 1.0E4 - <1.0E5 copies/mL (n=1051) | 8 ± 11 |
| Baseline: 1.0E5 - <1.0E6 copies/mL (n=1051) | 12 |
| Baseline: 1.0E6 - <1.0E7 copies/mL (n=1051) | 13 |
| Baseline: 1.0E7 - <1.0E8 copies/mL (n=1051) | 8 |
| Baseline: 1.0E8 - <1.0E9 copies/mL (n=1051) | 11 |
| Baseline: 1.0E9 - <1.0E10 copies/mL (n=1051) | 13 |
| Baseline: >= 1.0E10 copies/mL (n=1051) | 6 |
| Week 192: < 300 copies/mL (n=485) | 78 |
| Week 192: 300 - <1.0E3 copies/mL (n=485) | 3 |
| Week 192: 1.0E3 - <1.0E4 copies/mL (n=485) | 3 |
| Week 192: 1.0E4 - <1.0E5 copies/mL (n=485) | 4 |
| Week 192: 1.0E5 - <1.0E6 copies/mL (n=485) | 2 |
| Week 192: 1.0E6 - <1.0E7 copies/mL (n=485) | 2 |
| Week 192: 1.0E7 - <1.0E8 copies/mL (n=485) | 1 |
| Week 192: 1.0E8 - <1.0E9 copies/mL (n=485) | 5 |
| Week 192: 1.0E9 - <1.0E10 copies/mL (n=485) | 2 |
| Week 192: >= 1.0E10 copies/mL (n=485) | 0 |
An AE is a new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not be causally related to treatment. An SAE is an unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling. ALT=alanine transaminase; ULN=upper limit of normal.
| Participants | Entecavir, 0.5 or 1.0 mg QD, With or Without Lamivudine |
|---|---|
| Deaths on treatment | 18 |
| Deaths off treatment | 9 |
| SAEs on treatment | 169 |
| Discontinuations due to AEs on treatment | 14 |
| Any AE on treatment | 900 |
| Grade 3 and 4 AEs on treatment | 203 |
| Malignancies on and off treatment | 35 |
| ALT flares (ALT>2*entry and >10*ULN) on treatment | 32 |
| Hepatic disease progression on and off treatment | 33 |
| log10 copies/mL | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| At study entry (n=1051) | 6.14 ± 2.667 |
| Week 12 (n=1017) | 3.87 ± 1.749 |
| Week 24 (n=1010) | 3.62 ± 1.684 |
| Week 48 (n=905) | 3.37 ± 1.543 |
| Week 72 (n=769) | 3.31 ± 1.549 |
| Week 96 (n=691) | 3.34 ± 1.592 |
| Week 120 (n=629) | 3.32 ± 1.665 |
| Week 144 (n=597) | 3.34 ± 1.826 |
| Week 168 (n=514) | 3.18 ± 1.663 |
| Week 192 (n=485) | 3.19 ± 1.757 |
| Week 216 (n=455) | 3.20 ± 1.789 |
Observed values.
| Percentage of participants | Entecavir, 1.0 mg, With or Without Lamivudine |
|---|---|
| At study entry (n=1051) | 34 |
| Week 12 (n=935) | 40 |
| Week 24 (n=939) | 42 |
| Week 48 (n=864) | 46 |
| Week 72 (n=752) | 45 |
| Week 96 (n=679) | 50 |
| Week 120 (n=609) | 51 |
| Week 144 (n=587) | 53 |
| Week 168 (n=518) | 58 |
| Week 192 (n=491) | 60 |
| Week 216 (n=436) | 59 |
Observed values. Seroconversion=negative HBeAg with detectable anti-HBe antibody.
| Percentage of participants | Entecavir, 1.0 mg, With or Without Lamivudine |
|---|---|
| At study entry (n=1051) | 30 |
| Week 12 (n=931) | 33 |
| Week 24 (n=934) | 34 |
| Week 48 (n=862) | 36 |
| Week 72 (n=755) | 32 |
| Week 96 (n=678) | 34 |
| Week 120 (n=607) | 36 |
| Week 144 (n=587) | 37 |
| Week 168 (n=517) | 39 |
| Week 192 (n=491) | 42 |
| Week 216 (n=434) | 40 |
Observed values.
| U/L | Entecavir, 1.0 mg, With or Without Lamivudine |
|---|---|
| At study entry (n=1051) | 109.4 ± 170.5 |
| Week 12 (n=1049) | 48.77 ± 48.68 |
| Week 24 (n=1029) | 42.10 ± 36.83 |
| Week 48 (n=942) | 37.06 ± 34.20 |
| Week 72 (n=835) | 38.10 ± 41.90 |
| Week 96 (n=740) | 39.30 ± 46.35 |
| Week 120 (n=675) | 37.43 ± 28.97 |
| Week 144 (n=627) | 38.51 ± 38.95 |
| Week 168 (n=563) | 36.80 ± 29.06 |
| Week 192 (n=528) | 37.36 ± 30.44 |
| Week 216 (n=482) | 38.43 ± 55.09 |
ULN=upper limit of normal. ALT normalization=ALT levels ≤1.0\*ULN.
| Percentage of participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| At study entry (n=1019) | 40 |
| Week 48 (n=942) | 75 |
| Week 144 (n=627) | 74 |
| Week 216 (n=482) | 78 |
The Knodell Histologic Activity Index scores stage of necrosis and grade of inflammation in liver biopsies. Components are necrosis near the portal vein, intralobular degeneration and focal necrosis, portal inflammation, and fibrosis. The 4 components are scored from 1 to 4 and 1 to 10 (necrosis near the portal vein) and combined for a total score, with 22 being the highest possible score. Higher the score for each component=greater liver damage. Histologic improvement=a ≥2-point reduction in total Knodell score and no worsening in fibrosis. Cohort participants had to have adequate baseline and long-term biopsy samples and baseline Knodell necroinflammatory scores ≥2.
| Percentage of participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Histologic improvement (n=56) (Week 48) | 73 (60 to 84) |
| Histologic improvement (n=57) (Long-term biopsy) | 96 (88 to 100) |
The Ishak Modification for Hepatic Activity Index (HAI) scores necroinflammatory activity in chronic hepatitis. 0=no fibrosis, 1=fibrosis expansion of some portal areas, 2=fibrosis expansion of most portal areas, 3=fibrosis expansion of most portal areas with occasional bridging, 4=fibrosis expansion of portal areas with marked bridging, 5=incomplete cirrhosis, 6=probable or definite cirrhosis. Higher score=more severe necrosis. Improvement in fibrosis=≥1-point reduction in HAI score. Cohort participants had to have adequate baseline and long-term biopsy samples and baseline Knodell scores ≥2.
| Percentage of participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Improvement in fibrosis (n=56) (Week 48) | 32 (20 to 46) |
| Improvement in fibrosis (n=57) (Long-term biopsy) | 88 (76 to 95) |
Hemoglobin (g/dL): Grade (Gr) 1=9.5-11.0; Gr 2=8.0-\<9.5; Gr 3=6.5-\<8.0; Gr 4=\<6.5 White blood cells (cells/mm\^3): Gr 1=2,500-\<4,000; Gr 2=1,000-\<2,500; Gr 3=800-\<1,000; Gr 4=\<800. Neutrophils (cells/mm\^3): Gr 1=1000-\<1500; Gr 2=750-\<1000; Gr 3=500-\<750; Gr 4=\<500. Platelets (cells/mm\^3): Gr 1=75,000-99,000; Gr 2=50,000-\<75,000; Gr 3=20,000-\<50,000; Gr 4=\<20,000. Prothrombin time (seconds): Gr 1=1.01-\<1.26\*ULN; Gr 2=1.26-\<1.51 \*ULN; Gr 3=1.51-3\*ULN; Gr 4=\>3\*ULN. INR: Gr 1=1.24-1.5; Gr 2=1.5-2; Gr 3=2-3; Gr 4=\>3. INR=international normalized ratio; ULN=upper limit of normal. .
| Participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Hemoglobin (All grades) (n=1007) | 49 |
| White blood cells (All grades) (n=950) | 226 |
| Neutrophils (All grades) (n=1002) | 109 |
| Platelets (All grades) (n=979) | 51 |
| Protrombin time (All grades) (n=746) | 226 |
| INR (All grades)(n=746) | 214 |
| Hemoglobin (Grades 3-4) (n=1007) | 2 |
| White blood cells (Grades 3-4) (n=950) | 1 |
| Neutrophils (Grades 3-4) (n=1002) | 21 |
| Platelets (Grades 3-4) (n=979) | 1 |
| Prothrombin time (Grades 3-4) (n=746) | 21 |
| INR (Grades 3-4) (n=746) | 12 |
Amylase: Grade 1=1.10-\<1.40\*ULN; Grade 2=1.40-\< 2.10\*ULN; Grade 3=2.10-5.00\*ULN; Grade 4=\>5.00\*ULN. Lipase: Grade 1.1-\<1.4\*ULN; Grade 2=1.4-\<2.1\*ULN; Grade 3=2.1-5.0\*ULN; Grade 4=\>5.0\*ULN. Creatinine: Grade 1=1.10-\< 1.60\*ULN; Grade 2=1.60-\<3.10\*ULN; Grade 3=3.10-6.00\*ULN; Grade 4=\>6.00\*ULN. Blood urea nitrogen (BUN): Grade 1=1.25-\<2.60\*ULN; Grade 2=2.60-\<5.10\*ULN; Grade 3=5.10-10\*ULN; Grade 4=\>10\*ULN. ULN=upper limit of normal.
| Participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Amylase (All grades) (n=875) | 179 |
| Lipase (All grades) (n=390) | 126 |
| Amylase (Grades 3-4) (n=875) | 13 |
| Lipase (Grades 3-4) (n=390) | 38 |
| BUN/Urea (All grades) (n=998) | 57 |
| Creatinine (All grades) (n=1000) | 61 |
| BUN/Urea (Grades 3-4) (n=998) | 0 |
| Creatinine (Grades 3-4) (n=1000) | 2 |
Hypochloremia: Grade (Gr) 1=90-93; Gr 2=85-\<90; Gr 3=80-\<85; Gr 4=40-\<80. Hyperchloremia: Gr 1=113-\<117; Gr 2=117-\<121; Gr 3=121-125; Gr 4\>125. Hypocarbia: Gr 1=19-21; Gr 2=15-\<19; Gr 3=41-45; Gr 4=\>45. Hypercarbia: Gr 1=31-36; Gr 2=37-40; Gr 3=41-45; Gr 4=\>45. Hyponatremia: Gr 1=130-132; Gr 2=123-\<130; Gr 3=116-\<123; Gr 4\<116. Hypernatremia: Gr 1=148-\<151; Gr 2=151-\<158; Gr 3=158-165; Gr 4=\>165. Hypokalemia: Gr 1=3-3.4; Gr 2=2.5-\<3; Gr 3=2-\<2.5; Gr 4=\<2. Hyperkalemia: Gr 1=5.6-\<6.1; G2=6.1-\<6.6; Gr 3=6.6-7; Gr 4=\>7. Hypoglycemia: Gr 1=55-64; Gr 2=40-\<55; Gr 3=30-\< 40; G4=-\<30. Hyperglycemia: Gr 1=116-\<161; Gr 2=161-\<251; Gr 3=251-500; Gr 4\>500.
| Participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Hypochloremia (mEq/L) (All grades) (n=982) | 44 |
| Hyperchloremia (mEq/L) (All grades) (n=982) | 76 |
| Hypocarbia (mEq/L) (All grades) (n=831) | 285 |
| Hypercarbia (mEq/L) (All grades) (n=831) | 148 |
| Hyponatremia (mEq/L) (All grades) (n=1003) | 68 |
| Hypernatremia (mEq/L) (All grades) (n=1003) | 106 |
| Hypokalemia (mEq/L) (All grades) (n=993) | 135 |
| Hyperkalemia (mEq/L) (All grades (n=993) | 42 |
| Hypochloremia (mEq/L) (Grades 3-4) (n=982) | 3 |
| Hyperchloremia (mEq/L) (Grades 3-4) (n=982) | 7 |
| Hypocarbia (mEq/L) (Grades 3-4) (n=831) | 14 |
| Hypercarbia (mEq/L) (Grades 3-4) (n=831) | 2 |
| Hyponatremia (mEq/L)(Grades 3-4) (n=1003) | 2 |
| Hypernatremia (mEq/L) (Grades 3-4) (n=1003) | 5 |
| Hypokalemia (mEq/L) (Grades 3-4) (n=993) | 1 |
| Hyperkalemia (mEq/L) (Grades 3-4) (n=993) | 6 |
| Hypoglycemia (mg/dL) (All grades) (n=521) | 47 |
| Hyperglycemia (mg/dL) (All grades) (n=521) | 150 |
| Hypoglycemia (mg/dL) (Grades 3-4) (n=521) | 3 |
| Hyperglycemia (mg/dL) (Grades 3-4) (n=521) | 4 |
| Percentage of participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Overall Study: Percentage of Participants With a Confirmed ≥1 log10 Increase From Nadir in HBV DNA by PCR Assay | 18 |
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling. AST=aspartate aminotransferase; ULN=upper limit of normal.
| Participants | Entecavir, 0.5 or 1.0 mg QD, With or Without Lamivudine |
|---|---|
| Deaths on study | 13 |
| Malignant neoplasms | 17 |
| SAEs | 107 |
| Discontinuations due to AEs | 13 |
| Any AE | 842 |
| Grade 3 and 4 AEs | 156 |
| ALT flares (ALT>2*entry and >10*ULN) | 29 |
| ALT >5.0*ULN | 93 |
| AST >5.0*ULN | 53 |
| Total bilirubin >2.5*ULN | 22 |
| Lipase >2.0*ULN | 71 |
| Creatinine ≥0.5 mg/dL from baseline | 6 |
| Hypocarbia | 4 |
The Entecavir Continuous Treatment Cohort consisted of participants from study AI463-022 (NCT00035633) who were nucleoside-naive HBeAg-positive and enrolled in the current study with ≤35 days off treatment between the last dose in AI463-022 and the first dose in the current. This cohort is considered to be on continuous entecavir treatment and permitted assessment of continuous administration of entecavir in AI463-022 and the current study.
| Percentage of participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Week 48: HBV DNA <300 copies/mL (n=146) | 55 |
| Week 96: HBV DNA <300 copies/mL (n=140) | 83 |
| Week 144: HBV DNA <10^4 copies/mL (n=131) | 89 |
| Week 192: HBV DNA < 10^4 copies/mL (n=108) | 91 |
| Week 240: HBV DNA <300 copies/mL (n=94) | 94 |
| Week 48: Loss of HBeAg (n=146) | 1 |
| Week 96: Loss of HBeAg (n=140) | 4 |
| Week 144: Loss of HBeAg (n=132) | 30 |
| Week 192: Loss of HBeAg (n=111) | 39 |
| Week 240: Loss of HBeAg (n=95) | 41 |
| Week 48: Seroconversion (n=146) | 1 |
| Week 96: Seroconversion (n=140) | 3 |
| Week 144: Seroconversion (n=133) | 17 |
| Week 192: Seroconversion (n=111) | 16 |
| Week 240: Seroconversion (n=95) | 17 |
| Week 48: ALT ≤1.0*ULN (n=146) | 65 |
| Week 96: ALT ≤1.0*ULN (n=140) | 78 |
| Week 144: ALT ≤1.0*ULN (n=134) | 77 |
| Week 192: ALT ≤1.0*ULN (n=112) | 86 |
| Week 240: ALT ≤1.0*ULN (n=98) | 80 |
The Entecavir Retreatment Cohort consisted of participants who were nucleoside-naive, HBeAg-negative and enrolled from BMS study AI463-027 with \>60 days off treatment between the last dose in AI463-027 and the first dose in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as retreatment in the current study.
| Percentage of participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Week 48: HBV DNA <300 copies/mL (n=119) | 88 |
| Week 48: HBV DNA <10^4 copies/mL (n=88) | 87 |
| Week: 48: ALT ≤1.0*ULN (n=95) | 83 |
| Week 96: HBV DNA <300 copies/mL (n=74) | 91 |
| Week: 96: ALT ≤1.0*ULN (n=76) | 79 |
| Week 144: HBV DNA <300 copies/mL (n=57) | 95 |
| Week 144: ALT ≤1.0*ULN (n=66) | 86 |
The Lamivudine Continuous Switch Cohort consisted of participants who were nucleoside-naive, HBeAg-positive and received lamivudine in BMS study AI463-022 (NCT00035633) and enrolled in the current study with ≤35 days off treatment between end of dosing in AI463-022 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
| Percentage of participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| HBV DNA <300 copies/mL (n=147) | 58 |
| Achieved loss of HbeAg (n=129) | 25 |
| Achieved HBeAg seroconversion (n=129) | 8 |
| Achieved ALT ≤1.0*ULN (n=154) | 76 |
The Lamivudine Continuous Switch Cohort consisted of participants who were nucleoside-naive, HBeAg-positive and received lamivudine in BMS study AI463-022 (NCT00035633) and enrolled in the current study with ≤35 days off treatment between end of dosing in AI463-022 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
| Percentage of participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| HBV DNA <300 copies/mL (n=130) | 65 |
| Achieved ALT ≤1.0*ULN (n=135) | 68 |
An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. CTC Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling. ALT=alanine aminotransferase; ULN=upper limit of normal.
| Participants | Entecavir, 0.5 or 1.0 mg QD, With or Without Lamivudine |
|---|---|
| Deaths on study | 18 |
| Malignant neoplasms | 27 |
| SAEs | 135 |
| Discontinuations due to AEs | 11 |
| Any AE | 862 |
| Grade 3 and 4 AEs | 174 |
| ALT flares (ALT>2*entry and >10*ULN) | 30 |
| ALT >5.0*ULN | 175 |
| Total bilirubin >2.5*ULN | 32 |
| Lipase >2.0*ULN | 81 |
| Creatinine ≥0.3 mg/dL from baseline | 80 |
| Hypocarbia Grades 3-4 | 5 |
The Lamivudine Retreatment Switch Cohort consisted of participants who were nucleoside-naive HBeAg negative and enrolled from BMS study AI463-027 (NCT00035789) with \>60 days between end of dosing in AI463-027 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
| Percentage of participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| HBV DNA <300 copies/mL (n=69) | 97 |
| ALT ≤1.0*ULN (n=81) | 81 |
The Lamivudine Retreatment Switch Cohort consisted of participants who were nucleoside-naive HBeAg negative and enrolled from BMS study AI463-027 (NCT00035789) with \>60 days between end of dosing in AI463-027 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.
| Percentage of participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| HBV DNA <300 copies/mL (n=67) | 99 |
| Achieved ALT ≤1.0*ULN (n=73) | 85 |
The Amendment 11 Cohort consisted of participants who were hepatitis B e antigen (HBeAg) negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA \<300 copies/mL by PCR assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0\*ULN at the end of study drug dosing.ALT=alanine aminotransferase; ULN=upper limit of normal.
| Percentage of participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| End of dosing current study | 100 |
| Off-treatment Week 48 | 21 |
The Amendment 11 Cohort consisted of participants who were HBeAg negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA \<300 copies/mL by PCR Assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0\*ULN at the end of study drug dosing. ULN=upper limit of normal.
| Percentage of participants | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Off-treatment Week 48 <1000 copies/mL | 10 |
| Off-treatment Week 96 <1000 copies/mL | 10 |
| Off-treatment Week 48 <300 copies/mL | 7 |
| Off-treatment Week 96 <300 copies/mL | 3 |
| Off treatment Week 96 <10,000 copies/mL | 14 |
| Off treatment Week 48: ALT ≤1*ULN | 31 |
| Off treatment Week 96: ALT ≤1*ULN | 24 |
The Amendment 11 Cohort consisted of participants who were HBeAg negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA \<300 copies/mL by PCR assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0\*ULN at the end of study drug dosing.
| Log10 copies/mL | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Off-treatment Week 48 | 1.54 ± 0.336 |
| Off-treatment Week 96 | 1.18 ± 0.326 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adefovir, 10 mg | — | 7/35 (20%) | 27/35 (77.1%) |
| Entecavir, 0.02588 mg | — | 0/1 (0%) | 0/1 (0%) |
| Entecavir, 0.1 mg | — | 3/29 (10.3%) | 25/29 (86.2%) |
| Entecavir, 0.5 mg | — | 57/336 (17%) | 274/336 (81.5%) |
| Entecavir, 1.0 mg | — | 15/123 (12.2%) | 94/123 (76.4%) |
| Lamovidine, 100 mg | — | 87/523 (16.6%) | 439/523 (83.9%) |
| Missing | — | 0/2 (0%) | 2/2 (100%) |
| Placebo | — | 0/2 (0%) | 1/2 (50%) |
| Event | Adefovir, 10 mg | Entecavir, 0.02588 mg | Entecavir, 0.1 mg | Entecavir, 0.5 mg | Entecavir, 1.0 mg | Lamovidine, 100 mg | Missing | Placebo |
|---|---|---|---|---|---|---|---|---|
| PNEUMONIAInfections and infestations | 2/35 | 0/1 | 0/29 | 0/336 | 1/123 | 0/523 | 0/2 | 0/2 |
| SJOGREN'S SYNDROMEMusculoskeletal and connective tissue disorders | 0/35 | 0/1 | 1/29 | 0/336 | 0/123 | 0/523 | 0/2 | 0/2 |
| INFLAMMATIONGeneral disorders | 0/35 | 0/1 | 1/29 | 0/336 | 0/123 | 0/523 | 0/2 | 0/2 |
| LYMPHOPROLIFERATIVE DISORDERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/35 | 0/1 | 1/29 | 0/336 | 0/123 | 0/523 | 0/2 | 0/2 |
| LYMPHOMA CUTISNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/35 | 0/1 | 1/29 | 0/336 | 0/123 | 0/523 | 0/2 | 0/2 |
| VARICES OESOPHAGEALGastrointestinal disorders | 0/35 | 0/1 | 1/29 | 1/336 | 0/123 | 0/523 | 0/2 | 0/2 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 0/35 | 0/1 | 0/29 | 6/336 | 3/123 | 16/523 | 0/2 | 0/2 |
| CONSTIPATIONGastrointestinal disorders | 1/35 | 0/1 | 0/29 | 0/336 | 0/123 | 0/523 | 0/2 | 0/2 |
| CELLULITISInfections and infestations | 1/35 | 0/1 | 0/29 | 2/336 | 0/123 | 1/523 | 0/2 | 0/2 |
| DEVICE RELATED INFECTIONInfections and infestations | 1/35 | 0/1 | 0/29 | 0/336 | 0/123 | 0/523 | 0/2 | 0/2 |
| Event | Adefovir, 10 mg | Entecavir, 0.02588 mg | Entecavir, 0.1 mg | Entecavir, 0.5 mg | Entecavir, 1.0 mg | Lamovidine, 100 mg | Missing | Placebo |
|---|---|---|---|---|---|---|---|---|
| NAUSEAGastrointestinal disorders | 2/35 | 0/1 | 4/29 | 12/336 | 2/123 | 37/523 | 1/2 | 0/2 |
| LIPODYSTROPHY ACQUIREDSkin and subcutaneous tissue disorders | 0/35 | 0/1 | 0/29 | 0/336 | 1/123 | 0/523 | 0/2 | 1/2 |
| RESTLESS LEGS SYNDROMENervous system disorders | 0/35 | 0/1 | 0/29 | 1/336 | 0/123 | 0/523 | 1/2 | 0/2 |
| DERMATITISSkin and subcutaneous tissue disorders | 0/35 | 0/1 | 0/29 | 2/336 | 1/123 | 4/523 | 1/2 | 0/2 |
| TACHYCARDIACardiac disorders | 0/35 | 0/1 | 0/29 | 3/336 | 0/123 | 3/523 | 1/2 | 0/2 |
| INFLUENZA LIKE ILLNESSGeneral disorders | 0/35 | 0/1 | 1/29 | 10/336 | 3/123 | 18/523 | 1/2 | 0/2 |
| URINARY TRACT INFECTIONInfections and infestations | 3/35 | 0/1 | 0/29 | 18/336 | 3/123 | 29/523 | 1/2 | 0/2 |
| DYSPEPSIAGastrointestinal disorders | 3/35 | 0/1 | 8/29 | 25/336 | 10/123 | 44/523 | 1/2 | 0/2 |
| FOOD POISONINGGastrointestinal disorders | 0/35 | 0/1 | 0/29 | 1/336 | 0/123 | 2/523 | 1/2 | 0/2 |
| CONJUNCTIVITISEye disorders | 1/35 | 0/1 | 0/29 | 8/336 | 1/123 | 5/523 | 1/2 | 0/2 |
| Age, Customized(Years) | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Median | 41 ± 13 |
| Sex: Female, Male(Participants) | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Female | 241 |
| Male | 810 |
| Race/Ethnicity, Customized(Participants) | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Asian/Pacific Islander | 544 |
| White | 481 |
| Black/African American | 18 |
| Missing | 2 |
| Native Hawaiian/Other Pacific Islander | 2 |
| Other | 2 |
| Filipino | 1 |
| Hispanic/Latino | 1 |
| Region: Continent(Participants) | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Asia | 451 |
| Europe | 334 |
| North America | 141 |
| South America | 125 |
| Age(Years) | Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine |
|---|---|
| Mean | 41 (17 to 78) |
No study locations are listed for this record.
The record gives a start of Jan 2001, a primary completion of Dec 2009 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2012, 2 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Entecavir